Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blurring the line: measuring how astigmatism impacts vision after cataract surgery

NCT ID NCT06784063

Knowledge-focused Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at how residual astigmatism affects vision in people who have already received the Clareon Vivity extended vision intraocular lens (IOL) during cataract surgery. Researchers will temporarily induce astigmatism using trial lenses and measure changes in distance, intermediate, and near visual acuity. The goal is to quantify the impact of astigmatism on visual performance with this specific IOL.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clareon Vivity Extended Vision Intraocular Lens (IOL)
What this could lead to
If successful, this study could help eye surgeons understand how much astigmatism can be left uncorrected without harming visual performance after cataract surgery with this lens.
What could go wrong
This is a small, observational study with only 40 participants. It measures vision under artificial astigmatism in a lab setting, which may not reflect real-world conditions or long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Apr 2025

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to understand and sign an Institution Review Board-approved informed consent form; * Willing and able to attend all scheduled study visits as required by the protocol; * Implanted with study IOLs in both eyes at least 4 months prior to study participation; * Best Corrected Distance Visual Acuity (BCDVA) of 0 logarithm minimum angle of resolution (logMAR) or better in each eye. Exclusion Criteria: * Residual astigmatism greater than or equal to 1.00 diopter (D); * Clinically significant ocular conditions as specified in the protocol; * History of ocular surgeries other than limbal relaxing incisions * Other protocol-specified exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Astigmatism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astigmatism cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Astigmatism

Contacts and locations

Locations

  • Berkeley Eye Center

    Sugar Land, Texas, 77478, United States

  • Grosinger, Spigelman & Grey Eye Surgeons, P.C

    Bloomfield Hills, Michigan, 48302, United States

  • Key-Whitman Eye Center

    Dallas, Texas, 75243, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.